On Tuesday, Arbutus Biopharma Corp (NASDAQ: ABUS) opened lower -5.41% from the last session, before settling in for the closing price of $3.51. Price fluctuations for ABUS have ranged from $2.70 to $4.72 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 41.91%. Company’s average yearly earnings per share was noted 43.68% at the time writing. With a float of $148.63 million, this company’s outstanding shares have now reached $189.96 million.
The extent of productivity of a business whose workforce counts for 44 workers is very important to gauge. In terms of profitability, gross margin is 83.08%, operating margin of -1230.4%, and the pretax margin is -1133.04%.
Arbutus Biopharma Corp (ABUS) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Arbutus Biopharma Corp is 22.38%, while institutional ownership is 54.41%. The most recent insider transaction that took place on Apr 21 ’25, was worth 804,850. Before that another transaction happened on Apr 15 ’25, when Company’s Director proposed sale 53,114 for $3.20, making the entire transaction worth $170,098.
Arbutus Biopharma Corp (ABUS) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around 43.68% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 49.14% during the next five years compared to 33.46% growth over the previous five years of trading.
Arbutus Biopharma Corp (NASDAQ: ABUS) Trading Performance Indicators
Check out the current performance indicators for Arbutus Biopharma Corp (ABUS). In the past quarter, the stock posted a quick ratio of 8.15. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 103.03.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.38, a number that is poised to hit -0.10 in the next quarter and is forecasted to reach -0.10 in one year’s time.
Technical Analysis of Arbutus Biopharma Corp (ABUS)
The latest stats from [Arbutus Biopharma Corp, ABUS] show that its last 5-days average volume of 0.98 million was superior to 0.95 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 50.91%. Additionally, its Average True Range was 0.18.
During the past 100 days, Arbutus Biopharma Corp’s (ABUS) raw stochastic average was set at 56.88%, which indicates a significant increase from 44.52% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 41.69% in the past 14 days, which was lower than the 47.84% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.31, while its 200-day Moving Average is $3.59. Now, the first resistance to watch is $3.43. This is followed by the second major resistance level at $3.55. The third major resistance level sits at $3.60. If the price goes on to break the first support level at $3.26, it is likely to go to the next support level at $3.21. The third support level lies at $3.09 if the price breaches the second support level.
Arbutus Biopharma Corp (NASDAQ: ABUS) Key Stats
There are currently 191,480K shares outstanding in the company with a market cap of 635.71 million. Presently, the company’s annual sales total 6,170 K according to its annual income of -69,920 K. Last quarter, the company’s sales amounted to 1,570 K and its income totaled -12,530 K.
